Correlation Engine 2.0
Clear Search sequence regions

  • embryogenesis (1)
  • FGF19 (1)
  • FGF21 (1)
  • FGF23 (1)
  • FGFRs (1)
  • FGFs (8)
  • humans (1)
  • liver (1)
  • organogenesis (1)
  • Sizes of these terms reflect their relevance to your search.

    As key actors in embryogenesis and organogenesis, fibroblast growth factors (FGFs) can assume a protective or an aggravative role in pulmonary fibrosis pathophysiology. Among the FGFs, endocrine FGFs (FGF19, FGF21 and FGF23), are characterized by low affinity to FGF receptors (FGFRs), enabling them to deploy endocrine activity in several organs. More specifically, their anti-fibrotic role has been reported in liver, kidney or myocardial fibrosis. Endocrine FGFs are of growing interest on account of their potential anti-fibrotic role in pulmonary fibrogenesis, as well. In this review, we aim to summarize current knowledge on the protective effects of endocrine FGFs in pulmonary fibrosis. Copyright © 2023 SPLF. Published by Elsevier Masson SAS. All rights reserved.


    M Ghanem, A Mailleux, B Crestani. Fibroblast growth factor (FGF) endocrines and pulmonary fibrogenesis]. Revue des maladies respiratoires. 2023 Mar;40(3):239-242

    Expand section icon Mesh Tags

    Expand section icon Substances

    PMID: 36828676

    View Full Text